Introduction {#sec1-1}
============

Surgical repair of aortic coarctation is frequently associated with paradoxical hypertension. The incidence of hypertension is 56%--100% of cases.\[[@ref1][@ref2]\] The pathogenesis of paradoxical hypertension is not known well and may be related to the anatomical changes in the aorta,\[[@ref3]\] and the increased activity of the sympathetic nervous system.\[[@ref4]\] Surgical repair of coarctation is associated with a marked increase in plasma renin activity,\[[@ref5][@ref6]\] and elevated plasma norepinephrine concentration during the early phase of systolic hypertension and maintained elevated through the first 24--48 postoperative hours.\[[@ref4][@ref7][@ref8]\]

Dexmedetomidine is a highly selective alpha-2 agonist; it decreases the central sympathetic output and the release of epinephrine and norepinephrine\[[@ref9][@ref10][@ref11][@ref12]\] and also it decreases the release of renin and therefore it decreases the arterial blood pressure.\[[@ref13][@ref14]\]

The aim of the study was to assess the effect of dexmedetomidine on the incidence of paradoxical hypertension in pediatric patients undergoing aortic coarctation repair.

Methods {#sec1-2}
=======

After approval from the local Ethics Committee and obtaining written informed parental consent a randomized study included 108 children scheduled for elective repair of aortic coarctation. The inclusion criteria included patients with isolated aortic coarctation (diagnosed by echocardiography) without other congenital cardiac defects. Exclusion criteria were known allergy to the study medication, liver, renal, respiratory diseases, mental retardation, or psychological diseases. The patients received phenergan orally 0.5 mg/kg 2 h before surgery in the wards. The patients were transferred to the operative room and after attaching the monitors to patients, intravenous anesthetic induction by thiopental (3--5 mg/kg) or inhalational induction by sevoflurane, fentanyl (2 μg/kg), and rocuronium (0.6 mg/kg) and after tracheal intubation, the patients were ventilated mechanically. Two arterial lines were inserted (one in the right radial artery and another in the femoral artery), and then the central line was inserted in the right internal jugular vein. The anesthesia was maintained with an oxygen/air mixture (50:50), sevoflurane (1%-3%), fentanyl 1--3 μg/kg/min, and cisatracurium 1--2 μg/kg/min. The patients were randomly allocated (using simple randomization through a process of coin-tossing) into two equal groups (*n* = 54 each), and the study medications were prepared in 50 ml syringe by nursing staff and given to the anesthetist:

Group D (dexmedetomidine group): The patients received a loading dose of dexmedetomidine 0.5 μg/kg (started after insertion of the central line) over 10 min, followed by intravenous infusion 0.3 μg/kg/h by a computer-controlled infusion pump during the surgery and continued for the first 48 postoperative hours.Group C (control group): The patients received an equal amount of normal saline.

The surgery was done in the right lateral position. All patients received mannitol (20%) 0.25 g/kg before aortic cross-clamping. The repair was done by the resection of coarctation segment and end-to-end anastomosis of the proximal-to-distal aorta.

During aortic cross-clamping, the elevated blood pressure was controlled by the study medications, increased concentration of sevoflurane (1%--5%), and the addition of bolus doses of fentanyl (1--2 μg/kg). If the paradoxical hypertension after aortic declamping was not controlled well by sevoflurane (1%--5%), and bolus doses of fentanyl, nitroglycerine (0.5--10 μg/kg/min), sodium nitroprusside infusion (0.5--10 μg/kg/min), or esmolol infusion (0.50--200 μg/kg/min) was added and at the end of surgery, the patients were transferred to the pediatric cardiac surgical intensive care unit (ICU). The hypotension was treated with fluid administration and a bolus dose of ephedrine. Bradycardia was treated with a bolus dose of atropine (0.02 mg/kg). The patients were extubated according to the hemodynamic stability and parameters of extubation.

In ICU, oral antihypertensive medications (through a nasogastric tube), metoprolol 2 mg and enalapril 0.5 mg twice daily were started after confirmation of bowel sounds. After the first 48 postoperative hours, the study medications were stopped, while other medications such as nitroglycerine, nitroprusside, and esmolol were weaned gradually.

Monitoring of patients {#sec2-1}
----------------------

The monitors included the heart rate, arterial blood pressure (right radial artery and femoral artery), incidence, onset, severity and treatment of paradoxical hypertension, central venous pressure, arterial oxygen saturation, end-tidal carbon dioxide, and body temperature. The data were recorded before anesthesia induction and every 5 min during surgery. Arterial blood gases were checked every 30 min. End-tidal concentrations of sevoflurane were recorded every 5 min during the procedure (Dräger, Fabius GS, Premium Germany). In the pediatric cardiac surgical ICU, the same parameters were monitored every 5 min.

Outcomes {#sec2-2}
--------

The primary outcome was the incidence of paradoxical hypertension and the requirement for antihypertensive medications. The secondary outcome was the safety of the study medications. The safety was assessed by the occurrence of any adverse events to the patients.

Sample size calculation {#sec2-3}
-----------------------

Power analysis was performed using the Chi-square test for independent samples on the incidence of paradoxical hypertension in patients undergoing repair of aortic coarctation because it was the main outcome variable in the present study. A pilot study was conducted before starting this study because there are no available data in the literature for the incidence of paradoxical hypertension in patients undergoing repair of aortic coarctation with dexmedetomidine administration. The results of the pilot study showed the incidence of paradoxical hypertension was 20% in dexmedetomidine group and 45% in control group. Taking power 0.8 and alpha error 0.05, beta 0.2, a minimum sample size of 54 patients was calculated for each group.

Data were statistically described in terms of mean ± standard deviation or frequencies (number of cases) and percentages when appropriate. Comparison of numerical variables between the study groups was done using paired *t*-test. Within the group, comparison of numerical variables was done using repeated measures analysis of variance test using general linear model regression analysis. For comparing categorical data, Chi-square test was performed. The exact test was used instead when the expected frequency is \<5. *P* \< 0.05 was considered statistically significant. All statistical calculations were done using computer program SPSS (Statistical Package for the Social Science; SPSS Inc., Chicago, IL, USA) version 15 for Microsoft Windows.

Results {#sec1-3}
=======

[Figure 1](#F1){ref-type="fig"} shows the CONSORT diagram for the flow of participants through each stage of the present study. All patients completed the study and all patients were analyzed for the study.

![CONSORT diagram for the flow of participants through each stage of the present study](ACA-21-26-g001){#F1}

[Table 1](#T1){ref-type="table"} shows no significant differences regarding the demographic data, preoperative medications, and the type of aortic coarctation (*P* \> 0.05). There was no difference regarding the baseline systolic and diastolic blood pressure measured in the upper and lower limbs before anesthesia (*P* \> 0.05).

###### 

Preoperative data of patients

  Variables                  Group D (*n*=54)   Group C (*n*=54)   *P*
  -------------------------- ------------------ ------------------ -------
  Age (year)                 1.837±1.17         2.05±1.24          0.362
  Weight (kg)                12.15±4.83         11.931±4.87        0.808
  Sex                                                              
   Male                      29                 25                 0.441
   Female                    31                 23                 0.123
  Prostaglandin E1           2                  3                  0.647
  Captopril                  37                 31                 0.231
  Metoprolol                 7                  10                 0.428
  Captopril and metoprolol   10                 13                 0.480
  Aortic coarctation                                               
   Fresh                     48                 50                 0.506
   Redo                      6                  4                  0.506
  Blood pressure (mmHg)                                            
   Upper limb                                                      
    Systolic                 124.44±6.87        125.29±6.95        0.523
    Diastolic                93.81±8.23         94.55±7.64         0.628
   Lower limb                                                      
    Systolic                 63.74±5.08         64.50±4.34         0.406
    Diastolic                40.50±2.35         41.09±3.71         0.324

Data are presented as mean±SD, *n*. Group D: Dexmedetomidine group, Group C: Control group, SD: Standard deviation

There was no significant difference in the systolic and diastolic arterial blood pressure before the surgery and decreased after anesthesia in the patients of both groups, but the difference between the two groups was insignificant (*P* \> 0.05). After aortic cross-clamping, the blood pressure increased in patients of both groups, but the increase in Group C was higher than Group D (*P* \< 0.05), and controlled well by the study medication, increased concentration of sevoflurane, bolus doses of fentanyl, and addition of nitroglycerine and/or nitroprusside and the difference between the two groups was significant (*P* \< 0.05). The blood pressure decreased nearly to the level before aortic cross-clamping, but the comparison between the groups was significant (*P* = 0.039) \[Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}\]. After aortic declamping, 9 patients in Group D and 20 patients in Group C suffered from paradoxical hypertension (*P* = 0.011), and managed by sevoflurane (1%--5%), and bolus doses of fentanyl in addition to the infusion of nitroglycerine (0.5--10 μg/kg/min), sodium nitroprusside infusion (0.5--10 μg/kg/min), or esmolol infusion (0.50--200 μg/kg/min). The onset of paradoxical hypertension was earlier in Group C than Group D (*P* = 0.026). The degree of elevation (severity) in the paradoxical hypertension was higher in patients of Group C than patients of Group D (*P* = 0.017). The number of patients required for nitroglycerine was 4 patients in Group D and 20 patients in Group C (*P* = 0.001). The requirement for nitroprusside was 2 patients in Group D and 8 patients in Group C (*P* = 0.046). The esmolol was required for 6 patients in Group C and no patient in Group D required for esmolol (*P* = 0.011) \[Figure [2a](#F2){ref-type="fig"}, [2b](#F2){ref-type="fig"} and [Table 4](#T4){ref-type="table"}\]. The incidence of hypotension (hypotension as a side effect to dexmedetomidine or anesthetic medications and not to antihypertensive medications) was higher in Group D than Group C (*P* = 0.038) and treated by fluid administration and a bolus of ephedrine (2--5 mg).

###### 

Systolic arterial blood pressure of patients

  Time points   Group D (*n*=54)   Group C (*n*=54)   *P*
  ------------- ------------------ ------------------ ---------
  T0            124.44±6.87        125.29±6.95        0.523
  T1            118.72±3.52^†^     119.92±5.40^†^     0.173
  T2            127.00±10.80       132.09±10.28       0.013\*
  T3            124.90±8.78        129.45±10.08       0.014\*
  T4            118.90±5.62^†^     121.18±5.71        0.039\*
  T5            127.611±10.32      133.09±11.68       0.011\*
  T6            117.53±6.20^†^     120.51±6.59^†^     0.017\*
  T7            117.51±5.83^†^     120.20±6.33^†^     0.024\*
  T8            116.01±7.02^†^     119.14±7.25^†^     0.024\*
  T9            115.92±5.00^†^     118.11±6.18^†^     0.046\*
  T10           116.13±5.74^†^     118.75±5.09^†^     0.013\*
  T11           113.61±5.20^†^     116.11±6.16^†^     0.025\*
  T12           113.15±4.96^†^     115.98±6.25^†^     0.011\*
  T13           114.57±5.52^†^     116.74±5.35^†^     0.040\*

Data are presented as mean±SD. \**P*\<0.05 significant comparison between the two groups, ^†^*P*\<0.05 significant compared to the preoperative reading within the same group. T0: Reading at base line before anesthesia, T1: Reading before aortic cross-clamping, T2: Reading 15 min after aortic cross-clamping, T3: Reading 30 min after aortic cross-clamping, T4: Reading before aortic declamping, T5: Reading 15 min after aortic declamping, T6: Reading 30 min after aortic declamping, T7: Reading 1 h after aortic declamping, T8: Reading 1 h after ICU admission, T9: Reading 6 h after ICU admission, T10: Reading 12 h after ICU admission, T11: Reading 24 h after ICU admission, T12: Reading 48 h after ICU admission, T13: Reading 72 h after ICU admission. Group D: Dexmedetomidine group, Group C: Control group, SD: Standard deviation, ICU: Intensive Care Unit

###### 

Diastolic arterial blood pressure of patients

  Time points   Group D (*n*=54)   Group C (*n*=54)   *P*
  ------------- ------------------ ------------------ ---------
  T0            93.81±8.23         94.55±7.64         0.628
  T1            76.24±5.47^†^      79.01±7.87         0.035\*
  T2            85.09±7.41^†^      88.51±6.66^†^      0.013\*
  T3            76.27±7.59^†^      80.63±9.83^†^      0.011\*
  T4            71.61±5.07^†^      74.35±6.18^†^      0.013\*
  T5            95.72±5.30         98.704±7.28        0.017\*
  T6            78.20±7.67^†^      81.31±6.10^†^      0.021\*
  T7            76.37±7.01^†^      79.57±6.52^†^      0.015\*
  T8            74.01±6.48^†^      77.74±8.63^†^      0.013\*
  T9            73.50±5.76         76.09±7.37^†^      0.044\*
  T10           73.53±6.16^†^      76.33±6.97^†^      0.029\*
  T11           73.79±6.60^†^      77.07±6.79^†^      0.012\*
  T12           73.80±5.65^†^      76.45±7.11^†^      0.034\*
  T13           73.38±5.49^†^      76.03±5.96^†^      0.018\*

Data are presented as mean±SD. \**P*\<0.05 significant comparison between the two groups, ^†^*P*\<0.05 significant compared to the preoperative reading within the same group. T0: Reading at base line before anesthesia, T1: Reading before aortic cross-clamping, T2: Reading 15 min after aortic cross-clamping, T3: Reading 30 min after aortic cross-clamping, T4: Reading before aortic declamping, T5: Reading 15 min after aortic declamping, T6: Reading 30 min after aortic declamping, T7: Reading 1 h after aortic declamping, T8: Reading 1 h after ICU admission, T9: Reading 6 h after ICU admission, T10: Reading 12 h after ICU admission, T11: Reading 24 h after ICU admission, T12: Reading 48 h after ICU admission, T13: Reading 72 h after ICU admission. Group D: Dexmedetomidine group, Group C: Control group, SD: Standard deviation, ICU: Intensive Care Unit

![a: Systolic arterial blood pressure of patients; b: Diastolic arterial blood pressure of patients; c: Heart rate of patients. Group D: Dexmedetomidine group; Group C: Control group; T0: Reading at base line before anesthesia; T1: Reading before aortic cross-clamping; T2: Reading 15 min after aortic cross-clamping; T3: Reading 30 min after aortic cross-clamping; T4: Reading before aortic declamping; T5: Reading 15 min after aortic declamping; T6: Reading 30 min after aortic declamping; T7: Reading one hour after aortic declamping; T8: Reading one hour after ICU admission; T9: Reading 6 hours after ICU admission; T10: Reading 12 hours after ICU admission; T11: Reading 24 hours after ICU admission; T12: Reading 48 hours after ICU admission; T13: Reading 72 hours after ICU admission](ACA-21-26-g002){#F2}

###### 

Intraoperative data and outcome

  Variables                                     Group D (*n*=54)   Group C (*n*=54)   *P*
  --------------------------------------------- ------------------ ------------------ ---------
  Paradoxical hypertension                                                            
   Incidence                                    9                  20                 0.011\*
   Onset                                        16.87±6.35         14.15±6.24         0.026\*
   Severity                                     4                  14                 0.017\*
   Nitroglycerine                               4                  20                 0.001
   Nitroprusside                                2                  8                  0.046\*
   Esmolol                                      \-                 6                  0.011\*
  Hypotension                                   10                 3                  0.038\*
  Bradycardia                                   8                  2                  0.046\*
  Blood loss (ml)                               368.18±55.37       396.50±68.82       0.020\*
  End-tidal sevoflurane (%)                     1.60±0.49          1.83±0.57          0.026\*
  Fentanyl dose (µg/kg) during surgery          9.64±4.20          11.64±5.43         0.034\*
  Total fentanyl dose (µg/kg) in PSICU (48 h)   15.45±5.20         18.16±7.54         0.032\*
  End-tidal carbon dioxide (mmHg)               36.32±1.48         36.18±1.85         0.665
  Arterial oxygen saturation (%)                99.07±0.73         98.96±0.91         0.490
  Temperature (°C)                              37.02±0.31         37.08±0.25         0.270
  Duration of anesthesia (min)                  140.556±24.27      142.13±27.73       0.754
  Duration of surgery (min)                     116.48±21.92       119.25±28.30       0.570
  Mannitol (g)                                  3.92±1.20          3.82±1.18          0.667
  Aortic cross-clamping (min)                   37.59±7.69         35.611±6.93        0.162
  Urine output during surgery (ml)              150.92±28.03       139.25±24.86       0.024\*
  Extubation time (h)                           18.38±6.82         20.98±6.32         0.043\*
  ICU length of stay (days)                     4.12±0.96          4.16±1.01          0.830
  Hospital length of stay (days)                12.98±3.27         13.03±3.15         0.928
  Neurologic complications                      \-                 \-                 

Data are presented as mean±SD, *n* (%).\**P*\<0.05 significant comparison between the two groups. Group D: Dexmedetomidine group, Group C: Control group, SD: Standard deviation, ICU: Intensive Care Unit, PSICU: Pediatric cardiac surgical ICU

[Table 5](#T5){ref-type="table"} shows the changes in the heart rate of the patients of both groups. There was no significant difference before surgery (*P* \> 0.05), but the heart rate decreased after anesthesia in the patients of both groups, and the decrease was more in the patients of Group D than Group C (*P* \< 0.05) \[[Figure 2c](#F2){ref-type="fig"}\]. The incidence of bradycardia was higher in Group D than Group C (*P* = 0.046) and treated by bolus of atropine (0.02 mg/kg) \[[Table 4](#T4){ref-type="table"}\].

###### 

Heart rate of patients

  Time points   Group D (*n*=54)   Group C (*n*=54)   *P*
  ------------- ------------------ ------------------ ---------
  T0            111.68±6.91        110.88±6.30        0.533
  T1            108.66±4.53^†^     111.35±6.25        0.012\*
  T2            106.40±6.82^†^     109.44±7.52        0.030\*
  T3            106.31±6.18^†^     109.07±7.05^†^     0.033\*
  T4            104.75±6.44^†^     107.70±7.78^†^     0.034\*
  T5            105.92±5.03^†^     108.57±6.88^†^     0.024\*
  T6            104.14±5.28^†^     107.05±8.05^†^     0.029\*
  T7            105.13±4.31^†^     107.70±7.67^†^     0.034\*
  T8            104.64±5.42^†^     107.48±7.55^†^     0.027\*
  T9            104.59±6.10^†^     107.29±7.46^†^     0.042\*
  T10           105.44±7.00^†^     107.22±8.38^†^     0.215
  T11           105.27±7.19^†^     107.48±8.91^†^     0.160
  T12           106.33±5.72^†^     107.68±7.13^†^     0.280
  T13           105.33±7.12^†^     107.11±9.35^†^     0.269

Data are presented as mean±SD. \**P*\<0.05 significant comparison between the two groups, ^†^*P*\<0.05 significant compared to the preoperative reading within the same group. T0: Reading at base line before anesthesia, T1: Reading before aortic cross-clamping, T2: Reading 15 min after aortic cross-clamping, T3: Reading 30 min after aortic cross-clamping, T4: Reading before aortic declamping, T5: Reading 15 min after aortic declamping, T6: Reading 30 min after aortic declamping, T7: Reading 1 h after aortic declamping, T8: Reading 1 h after ICU admission, T9: Reading 6 h after ICU admission, T10: Reading 12 h after ICU admission, T11: Reading 24 h after ICU admission, T12: Reading 48 h after ICU admission, T13: Reading 72 h after ICU admission. Group D: Dexmedetomidine group, Group C: Control group, SD: Standard deviation, ICU: Intensive Care Unit

[Table 6](#T6){ref-type="table"} shows no difference in the central venous pressure between the two groups through the study (*P* \> 0.05).

###### 

Central venous pressure of patients

  Time points   Group D (*n*=54)   Group C (*n*=54)   *P*
  ------------- ------------------ ------------------ -------
  T0            10.53±1.46         10.22±1.73         0.316
  T1            9.89±1.93          10.02±1.69         0.710
  T2            10.45±1.28         10.73±1.53         0.304
  T3            11.30±1.61         10.76±1.75         0.098
  T4            11.22±1.35         10.83±1.52         0.161
  T5            10.77±1.60         10.41±1.33         0.206
  T6            11.25±1.37         11.42±1.64         0.560
  T7            11.13±1.44         11.42±1.36         0.284
  T8            10.75±1.92         11.20±1.57         0.185
  T9            10.24±1.65         11.39±1.32         0.219
  T10           9.75±1.80          10.12±1.57         0.257
  T11           10.48±1.55         10.64±1.36         0.569
  T12           10.45±1.70         10.72±1.58         0.356
  T13           10.73±1.40         10.47±1.59         0.369

Data are presented as mean±SD. \**P*\<0.05 significant comparison between the two groups, ^†^*P*\<0.05 significant compared to the preoperative reading within the same group. T0: Reading at base line before anesthesia, T1: Reading before aortic cross-clamping, T2: Reading 15 min after aortic cross-clamping, T3: Reading 30 min after aortic cross-clamping, T4: Reading before aortic declamping, T5: Reading 15 min after aortic declamping, T6: Reading 30 min after aortic declamping, T7: Reading 1 h after aortic declamping, T8: Reading 1 h after ICU admission, T9: Reading 6 h after ICU admission, T10: Reading 12 h after ICU admission, T11: Reading 24 h after ICU admission, T12: Reading 48 h after ICU admission, T13: Reading 72 h after ICU admission. Group D: Dexmedetomidine group, Group C: Control group, SD: Standard deviation, ICU: Intensive Care Unit

[Table 4](#T4){ref-type="table"} shows the intra- and post-operative data of the patients. The end-tidal sevoflurane was lower in Group D than Group C (*P* = 0.026). The total dose of fentanyl was lower in Group D than Group C during surgery (*P* = 0.034) and during postoperative pediatric cardiac ICU (*P* = 0.032). There was no significant difference between the two groups in the arterial oxygen saturation (*P* = 0.665), end-tidal carbon dioxide (*P* = 0.490), temperature (*P* = 0.270), duration of anesthesia (*P* = 0.754), duration of surgery (*P* = 0.570), mannitol dosage (*P* = 0.667), and aortic cross-clamping duration (*P* = 0.162). The amount of blood loss decreased with dexmedetomidine compared to the control group (*P* = 0.020). The amount of urine output during surgery increased significantly in patients of Group D than Group C (*P* = 0.024). The extubation was earlier in patients of Group D than Group C (*P* = 0.043). There was no significant difference between the two groups regarding the ICU length of stay (*P* = 0.830) and hospital length of stay (*P* = 0.928). There were no neurological complications in patients of both groups.

Discussion {#sec1-4}
==========

Despite the growing interest in the perioperative uses of dexmedetomidine for pediatric patients with congenital heart disease, its effect on paradoxical hypertension in pediatric patients undergoing aortic coarctation repair is limited. The present study showed that the dexmedetomidine decreased the incidence and severity of the paradoxical hypertension in pediatric patients undergoing aortic coarctation repair. Furthermore, it delayed the onset of occurrence of paradoxical hypertension and decreased the required medications for the treatment of paradoxical hypertension. Dexmedetomidine decreased the required doses of fentanyl and sevoflurane compared to the control group.

Sahu *et al*.\[[@ref15]\] documented that dexmedetomidine is a safe drug and used as an adjunct for nitroglycerin and nitroprusside in the management of severe paradoxical hypertension. The paradoxical hypertension was severe and not controlled well by nitroglycerin and nitroprusside in the immediate postoperative period in two cases of aortic coarctation repair. After adding dexmedetomidine (0.5 μg/kg/h), the blood pressure was controlled. Furthermore, it helps a smooth transition from intravenous medications to oral drugs to control the blood pressure at a constant level without wide fluctuations in the hemodynamics. Bhana *et al*.\[[@ref16]\] reported that dexmedetomidine is effective and safe to control the hypertension.

Klamt *et al*.\[[@ref17]\] evaluated the effects of dexmedetomidine (1 μg/kg/h) with fentanyl infusion on blood pressure and heart rate during cardiac surgery in children (aged 1 month--10 years) undergoing surgery to repair congenital heart disease with cardiopulmonary bypass and they found that the systolic blood pressure decreased significantly after 1 h of dexmedetomidine infusion.

Another study evaluated the effect of dexmedetomidine (a loading dose of 1 μg/kg) over 15 min before induction followed by infusion of 0.3 μg/kg/h during the procedure in high-risk adult patients who underwent aortic vascular surgery with aortic cross-clamping and showed that the dexmedetomidine minimized the fluctuations in arterial blood pressure before, during, and after aortic cross-clamping, and it provides myocardial protection in high-risk patients.\[[@ref18]\]

The systolic and diastolic arterial blood pressure decreased with dexmedetomidine compared to the control group and this may be related to many factors: (1) the decrease in heart rate with dexmedetomidine;\[[@ref19][@ref20][@ref21][@ref22][@ref23]\] (2) the decrease of catecholamines release;\[[@ref9][@ref10][@ref11][@ref12]\] (3) the inhibitory effect on the renin-angiotensin system;\[[@ref13][@ref14]\] (4) the diuretic effect and increased amount of urine output;\[[@ref12][@ref14]\] (5) it provides sedation and analgesia, and preserving the psychomotor function while the patients are calm and resting comfortably.\[[@ref24]\]

Tokuhira *et al*.\[[@ref25]\] studied the effect of dexmedetomidine (0.3--0.4 μg/kg/h without a loading dose), for postoperative sedation in 9 pediatric patients who had undergone Fontan procedure for congenital heart disease and reported a stable mean arterial blood pressure and central venous pressure.

Nishibe *et al*.\[[@ref26]\] showed that the perioperative dexmedetomidine infusion (0.4--0.8 μg/kg/h) decreased the pulmonary artery pressure and transpulmonary pressure gradient after a bidirectional superior cavopulmonary shunt in 29 pediatric patients \< 12 months of age and the same finding was reported by Lazol *et al*.\[[@ref27]\]

Contrary to the present study, Friesen *et al*.\[[@ref28]\] studied the effects of dexmedetomidine loading (1 μg/kg, 0.75 μg/kg, or 0.5 μg/kg) on the hemodynamics of children undergoing cardiac catheterization and they documented that the mean arterial blood pressure and indexed systemic vascular resistance increased significantly.

The heart rate decreased with dexmedetomidine compared to the control group, and this may be mediated by enhancement of vagal neural activity,\[[@ref19][@ref20]\] depression of the sinus node, and atrioventricular node,\[[@ref21][@ref22]\] in addition to the decrease in catecholamines release in the blood.\[[@ref29]\] The decrease in heart rate resulted in a decrease in cardiac output, therefore decrease in blood pressure.\[[@ref30][@ref31][@ref32][@ref33]\]

The amount of blood loss decreased in the dexmedetomidine group compared to the control group, and this may be a result of decreased blood pressure with dexmedetomidine more than the control group.\[[@ref34][@ref35][@ref36]\]

Dexmedetomidine increased the urine output, and this may be related to the inhibitory effect of dexmedetomidine on the renin angiotensin system, antidiuretic hormones,\[[@ref14]\] and the increase of atrial natriuretic peptide release resulting in natriuresis.\[[@ref37]\]

The extubation time was shorter with dexmedetomidine compared to the control group, and this may be related to the decreased dose of fentanyl.\[[@ref38][@ref39]\]

The present study showed that the dexmedetomidine was associated with hypotension and bradycardia more the control group and these findings were documented by previous studies.\[[@ref16][@ref40][@ref41][@ref42]\]

Our study recognizes some limitations such as a small number of patients and limited articles which studied the effect of dexmedetomidine on the paradoxical hypertension to compare the results of the present study.

Conclusion {#sec1-5}
==========

Dexmedetomidine is safe in pediatric patients undergoing aortic coarctation repair. It minimized the incidence and severity of paradoxical hypertension and delayed its onset. It decreased the requirement for the antihypertensive, inhalational agents, and opioids. Hypotension and bradycardia are the most common side effect of dexmedetomidine.

Financial support and sponsorship {#sec2-4}
---------------------------------

Nil.

Conflicts of interest {#sec2-5}
---------------------

There are no conflicts of interest.

The authors appreciate the help and support of the staff-nurses in the operative rooms and pediatric cardiac ICU to achieve this work.
